Mack Mariah, Nichols Laura, Guerrero Dubert M
Internal Medicine, University of North Dakota School of Medicine and Health Sciences, Fargo, USA.
Internal Medicine, Sanford Health, Fargo, USA.
Cureus. 2021 May 13;13(5):e15004. doi: 10.7759/cureus.15004.
Rhabdomyolysis has been described as a complication of coronavirus disease 2019 (COVID-19) infection, but few cases of rhabdomyolysis associated with COVID-19 vaccination have been reported. We described a case of an 80-year-old male who developed rhabdomyolysis two days after receiving his second dose of the Moderna COVID-19 vaccine. He presented with severe weakness, myalgias, and an initial creatinine kinase (CK) of 6,546 IU/L that improved with intravenous fluids. Common causes of rhabdomyolysis were excluded including statin use, strenuous exercise, and trauma. With the increasing immunization efforts against COVID-19, physicians should consider the possibility of rhabdomyolysis when a patient presents with neuromuscular complaints following vaccination.
横纹肌溶解症已被描述为2019冠状病毒病（COVID-19）感染的一种并发症，但与COVID-19疫苗接种相关的横纹肌溶解症病例报告较少。我们描述了一例80岁男性病例，该患者在接种第二剂Moderna COVID-19疫苗两天后出现横纹肌溶解症。他表现为严重虚弱、肌痛，初始肌酸激酶（CK）为6546 IU/L，经静脉补液后有所改善。排除了横纹肌溶解症的常见病因，包括他汀类药物使用、剧烈运动和创伤。随着针对COVID-19的免疫接种工作不断增加，当患者在接种疫苗后出现神经肌肉症状时，医生应考虑横纹肌溶解症的可能性。
